CorMedix Inc.

CorMedix Inc.

CRMDNYSE / NASDAQHealthcareSmall cap

$5.27+$0.19 (+3.7%)

Last close · Data as of Nov 20, 2026

Market cap
$670.0M
P/E
4.1x
EV / EBITDA
4.0x
Revenue
$311.7M
Net margin
52.0%
ROCE
27.8%

-45.8% over the last year

CorMedix Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-30.4%
3M
-36.0%
6M
-33.5%
1Y
-45.8%
5Y
Hidden
  • This period includes a one-day price step on 9 Aug 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change +$0.19 (+3.7%) from $5.08 to $5.27 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CRMD, bought on each weekday since 2021.

News & filings

What CorMedix filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 55.0 times interest costs.

Concerns (1)

  • The price is 29.7% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Sector
Healthcare
Shares outstanding
79.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$670.0M
P/E
4.1x
P/B
1.7x
EV / EBITDA
4.0x
EV / Sales
2.2x
P/S
2.1x
52-week high
$12.73
52-week low
$4.50

Profitability

Operating margin
48.2%
Net margin
52.0%
EBITDA margin
53.7%
ROE
40.0%
ROCE
27.8%
ROIC
37.3%
ROA
19.6%
Asset turnover
0.38

Growth

Revenue
$311.7M
Revenue growth, 1Y
617.0%
Revenue CAGR, 3Y
1582.8%
Net profit growth, 1Y
-1009.4%
Free cash flow
$172.8M

Solvency

Current ratio
2.11
Debt / Equity
0.37
Debt / Assets
0.18
CFO / Net profit
1.08
Cash / Market cap
22.2%

Where the revenue went

Of every $100 of FY2025 revenue, $52 was left as net income.

CorMedix Inc. income statement flow, FY2025
CorMedix Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$36.0M
RevenueGross profit$275.8M
Gross profitResearch and development$19.3M
Gross profitSelling, general and administrative$106.3M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$150.1M
Operating incomePretax income$150.0M
Operating incomeInterest and other expense$120.0k
Pretax incomeNet income$150.0M
Tax benefit and otherNet income$13.0M

Revenue and net profit

Revenue grew 617.0% in FY2025; net profit is the dashed line.

CorMedix Inc. revenue and net profit by fiscal year
CorMedix Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$65.4k-$29.7M
FY2023$0.00-$46.3M
FY2024$43.5M-$17.9M
FY2025$311.7M$163.1M

Cash flows

FY2025: $175.0M from operations, $172.8M free after investment (dashed).

CorMedix Inc. operating and free cash flow by fiscal year
CorMedix Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$24.4M-$24.6M
FY2023-$38.4M-$38.7M
FY2024-$50.6M-$50.7M
FY2025$175.0M$172.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$311.7M+617.0%1Y
EBITDA
$167.3M
Net profit
$163.1M
Cash from operations
$175.0M
Free cash flow
$172.8M
Revenue CAGR, 3Y
1582.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$311.7M$167.3M$163.1M$172.8M40.2%+617.0%-1009.4%

Monthly returns

Month-by-month returns of CRMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$826.1M
Liabilities$420.8M
Equity$405.3M
Paid-in capital$581.8M
Retained earnings-$176.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CRMD highlighted.

P/E against peers

CRMD trades at 4.1x earnings against a peer median of -9.6x.

  1. CorMedix Inc. (this company)4.1x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Allogene Therapeutics, Inc., Aura Biosciences, Inc., Candel Therapeutics, Inc., Design Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
CorMedix Inc.CRMDthis company$670.0M4.1x1.7x40.0%4.0x
Allogene Therapeutics, Inc.ALLO$704.1M-3.7x2.4x-65.3%-4.1x
Aura Biosciences, Inc.AURA$703.0M-6.6x5.1x-77.6%-5.9x
Candel Therapeutics, Inc.CADL$679.2M-17.8x13.1x-73.5%-17.3x
Design Therapeutics, Inc.DSGN$672.0M-9.6x3.2x-32.8%-8.3x
Zevra Therapeutics, Inc.ZVRA$660.3M7.9x4.3x53.8%6.7x
SI-BONE, Inc.SIBN$659.9M—3.7x-10.6%—
Aclaris Therapeutics, Inc.ACRS$657.8M-10.1x6.4x-63.0%—
Castle Biosciences, Inc.CSTL$655.1M-27.1x1.4x-5.1%50.7x
Peer median—-9.6x4.0x-47.9%-5.0x

Year-to-date ROI

CRMD since 1 January, against earlier years.

Historical volatility

CRMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

CorMedix Inc. operating margin by fiscal year
CorMedix Inc. operating margin by fiscal year
DateOperating margin
FY2022-43742.9%
FY2023—
FY2024-51.4%
FY202548.2%
LineFY2025
Cost of revenueCost Of Revenue$36.0M
Gross profitGross Profit$275.8M
Operating expensesOperating Expense$125.6M
Research and developmentResearch And Development$19.3M
Total expensesTotal Expenses$161.6M
Pretax incomePretax Income$150.0M

Learn while you research

Academy chapters picked for CorMedix Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 4.1 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing617% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →